Vaxcyte (PCVX) Competitors $86.53 +0.32 (+0.37%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PCVX vs. TAK, BNTX, TEVA, BGNE, MRNA, VTRS, SMMT, GMAB, RDY, and SRPTShould you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Takeda Pharmaceutical (TAK), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. Vaxcyte vs. Takeda Pharmaceutical BioNTech Teva Pharmaceutical Industries BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Takeda Pharmaceutical (NYSE:TAK) and Vaxcyte (NASDAQ:PCVX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability. Do analysts recommend TAK or PCVX? Vaxcyte has a consensus price target of $145.71, indicating a potential upside of 68.40%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts plainly believe Vaxcyte is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation and earnings, TAK or PCVX? Takeda Pharmaceutical has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$4.55T0.01$994.06M$0.5822.59VaxcyteN/AN/A-$402.27M-$4.60-18.81 Is TAK or PCVX more profitable? Takeda Pharmaceutical has a net margin of 6.49% compared to Vaxcyte's net margin of 0.00%. Takeda Pharmaceutical's return on equity of 10.00% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical6.49% 10.00% 4.78% Vaxcyte N/A -23.53%-22.20% Does the MarketBeat Community prefer TAK or PCVX? Takeda Pharmaceutical received 55 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 75.00% of users gave Vaxcyte an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformTakeda PharmaceuticalOutperform Votes10056.82% Underperform Votes7643.18% VaxcyteOutperform Votes4575.00% Underperform Votes1525.00% Which has more risk & volatility, TAK or PCVX? Takeda Pharmaceutical has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Do insiders & institutionals have more ownership in TAK or PCVX? 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 3.1% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer TAK or PCVX? In the previous week, Vaxcyte had 11 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 13 mentions for Vaxcyte and 2 mentions for Takeda Pharmaceutical. Vaxcyte's average media sentiment score of 0.65 beat Takeda Pharmaceutical's score of 0.61 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryVaxcyte beats Takeda Pharmaceutical on 9 of the 17 factors compared between the two stocks. Ad Behind the MarketsWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.Take these 4 steps today to protect your retirement NOW Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCVX vs. The Competition Export to ExcelMetricVaxcyteBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.78B$2.94B$5.07B$9.08BDividend YieldN/A1.90%4.87%4.21%P/E Ratio-18.8145.9499.0517.15Price / SalesN/A411.851,121.17116.80Price / CashN/A182.1041.5237.88Price / Book6.643.894.754.78Net Income-$402.27M-$42.21M$119.33M$225.60M7 Day Performance-1.36%-2.14%-1.86%-1.23%1 Month Performance-2.10%4.21%11.40%3.07%1 Year Performance45.77%18.39%30.26%16.48% Vaxcyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCVXVaxcyte1.6118 of 5 stars$86.53+0.4%$145.71+68.4%+45.4%$10.78BN/A-18.81160Analyst ForecastInsider TradeHigh Trading VolumeTAKTakeda Pharmaceutical4.3889 of 5 stars$13.33-0.7%N/A-4.3%$42.41B$28.20B23.1449,281BNTXBioNTech1.896 of 5 stars$113.79-5.5%$140.76+23.7%+10.0%$27.05B$3.04B-56.016,133TEVATeva Pharmaceutical Industries1.8771 of 5 stars$16.66+1.0%$19.67+18.0%+112.2%$18.87B$16.77B-19.7937,851Analyst DowngradeOptions VolumeNews CoverageBGNEBeiGene2.6066 of 5 stars$176.72-1.5%$253.69+43.6%+0.7%$17.22B$2.46B-21.7710,600MRNAModerna4.255 of 5 stars$41.65-0.4%$79.50+90.9%-54.3%$16.03B$5.06B-7.195,600Analyst DowngradeVTRSViatris2.0866 of 5 stars$12.69+0.5%$13.67+7.7%+19.8%$15.15B$15.05B-17.0738,000News CoverageSMMTSummit Therapeutics3.2652 of 5 stars$18.81+5.5%$33.33+77.2%+636.9%$13.87B$700,000.00-63.68105News CoverageGap DownGMABGenmab A/S4.1997 of 5 stars$20.14-0.1%$45.20+124.4%-33.5%$13.33B$19.84B19.582,204Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories1.8457 of 5 stars$14.77+2.1%$17.00+15.1%+15.8%$12.33B$299.87B22.9527,048Analyst DowngradeNews CoverageSRPTSarepta Therapeutics4.8825 of 5 stars$125.93+1.8%$178.71+41.9%+31.8%$12.03B$1.64B98.971,314Analyst ForecastPositive News Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors BioNTech Competitors Teva Pharmaceutical Industries Competitors BeiGene Competitors Moderna Competitors Viatris Competitors Summit Therapeutics Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Sarepta Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PCVX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PCVX Stock Alerts